Goodwin advised Gandeeva on the deal. Gandeeva announced its Series A funding led by Lux Capital and Leaps by Bayer, with participation from Obvious Ventures, Amgen Ventures,...
Gandeeva’s $40 Million Series A Funding
Novo’s $90 Million Series B Preferred Stock Financing
Goodwin Procter advised Novo on the deal. Novo announced the completion of its $90 million Series B Preferred Stock financing that values the startup at $700 million....
Amylyx Pharmaceuticals’ $190 Million IPO
Wilmer Cutler Pickering Hale and Dorr advised the underwriters on the deal while Goodwin Procter represented Amylyx Pharmaceuticals. Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company...
SWORD Health’s $163 Million Series D Financing
Goodwin Procter advised SWORD Health on the deal. SWORD Health announced its Series D financing. This brings the total primary and secondary transactions to more than $320...
Amplitude’s Direct listing of Class A Common Stock
Goodwin advised Morgan Stanley on the deal, while Latham & Watkins represented Amplitude. Amplitude, Inc., a pioneer in digital optimization, announced that, as of September 22, 2021,...
Sorare’s $680 Million Series B Financing Round
Orrick advised Sorare on the deal. Latham & Watkins advised Atomico. White & Case advised SoftBank Vision Fund II. Hogan Lovells has advised Accel, Eurazeo and...
Absci Corporation’s $200 Million Initial Public Offering
Goodwin Procter advised Absci, while Latham & Watkins represented the underwriters in the offering. Absci Corporation (Absci), the synthetic biology company unlocking the potential of proteins...
Rapid Micro Biosystems’ $158.4 Million IPO
Goodwin Procter advised the underwriters, while Latham & Watkins represented Rapid Micro Biosystems, Inc. in the offering. Rapid Micro Biosystems, Inc. (Nasdaq: RPID), an innovative life sciences...
Blend’s IPO
Wilson Sonsini Goodrich & Rosati advised Blend on the deal while Goodwin Procter represented the underwriters. Blend Labs, Inc. announced the pricing of its initial public...
Nimbus Therapeutics’ $105 Million Private Financing Round
Goodwin Procter LLP advised Nimbus Therapeutics on the deal. Nimbus Therapeutics announced the closing of a $105 million private financing round which was led by BVF Partners...
Bright Health Group’s $924.3 Million IPO
Goodwin Procter LLP advised the underwriters on the deal, while Simpson Thacher represented Bright Health Group. Bright Health Group announced the pricing of its initial public...
Doximity’s $605.8 Million IPO
Goodwin Procter LLP advised Doximity on the deal. Doximity (NYSE: DOCS) announced its initial public offering of 23,300,000 shares of its Class A common stock at a...